- Home
- BAK vs NVAX Comparison
BAK vs NVAX Comparison
Compare BAK & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAK
- NVAX
- Stock Information
- Founded
- BAK 1972
- NVAX 1987
- Country
- BAK Brazil
- NVAX United States
- Employees
- BAK N/A
- NVAX N/A
- Industry
- BAK Major Chemicals
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BAK Industrials
- NVAX Health Care
- Exchange
- BAK Nasdaq
- NVAX Nasdaq
- Market Cap
- BAK 1.7B
- NVAX 2.0B
- IPO Year
- BAK N/A
- NVAX 1995
- Fundamental
- Price
- BAK $4.11
- NVAX $9.00
- Analyst Decision
- BAK Strong Buy
- NVAX Buy
- Analyst Count
- BAK 3
- NVAX 6
- Target Price
- BAK $9.75
- NVAX $17.83
- AVG Volume (30 Days)
- BAK 1.2M
- NVAX 3.6M
- Earning Date
- BAK 11-06-2024
- NVAX 11-12-2024
- Dividend Yield
- BAK N/A
- NVAX N/A
- EPS Growth
- BAK N/A
- NVAX N/A
- EPS
- BAK N/A
- NVAX N/A
- Revenue
- BAK $13,764,416,401.00
- NVAX $885,193,000.00
- Revenue This Year
- BAK $14.26
- NVAX N/A
- Revenue Next Year
- BAK $8.26
- NVAX N/A
- P/E Ratio
- BAK N/A
- NVAX N/A
- Revenue Growth
- BAK 2.86
- NVAX N/A
- 52 Week Low
- BAK $4.07
- NVAX $3.53
- 52 Week High
- BAK $10.98
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- BAK 27.12
- NVAX 49.30
- Support Level
- BAK $4.07
- NVAX $8.13
- Resistance Level
- BAK $4.35
- NVAX $9.75
- Average True Range (ATR)
- BAK 0.22
- NVAX 0.46
- MACD
- BAK -0.05
- NVAX 0.12
- Stochastic Oscillator
- BAK 11.76
- NVAX 48.15
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.